Generex Biotechnology Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNBT research report →
Companygenerex.com/index.html
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer.
- CEO
- Joseph Moscato
- IPO
- 1998
- Employees
- 15
- HQ
- Miramar, FL, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.24%
- Op Margin
- -673.54%
- Net Margin
- -1252.72%
- ROE
- 216.76%
- ROIC
- -88.91%
Growth & Income
- Revenue
- $2.66M · -57.11%
- Net Income
- $-33,335,000 · -256.87%
- EPS
- $-0.46 · -228.57%
- Op Income
- $-17,923,000
- FCF YoY
- 38.06%
Performance & Tape
- 52W High
- $0.14
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- -0.06
- Avg Volume
- 18.59K
Get TickerSpark's AI analysis on GNBT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 19 | Prioletti Mark Joseph SE | other | 0 |
| May 14, 19 | Salvo Lawrence Anthony Sr | other | 0 |
| Dec 4, 18 | Haines Harold Gray | buy | 945 |
| Dec 4, 18 | Haines Harold Gray | buy | 555 |
| Dec 7, 18 | Haines Harold Gray | buy | 8,000 |
| Dec 7, 18 | Haines Harold Gray | buy | 300 |
| Oct 3, 18 | Ro Andrew | other | 4,500 |
| Oct 3, 18 | Purcell Richard David Jr. | other | 4,500 |
| Oct 3, 18 | MCGEE BRIAN | other | 1,000 |
| Oct 3, 18 | Lyman Gary Herbert | other | 1,000 |
Our GNBT Coverage
We haven't published any research on GNBT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GNBT Report →